[go: up one dir, main page]

WO2000001813A3 - Peptide inhibitors of androgen-independent activation of androgen receptor - Google Patents

Peptide inhibitors of androgen-independent activation of androgen receptor Download PDF

Info

Publication number
WO2000001813A3
WO2000001813A3 PCT/CA1999/000604 CA9900604W WO0001813A3 WO 2000001813 A3 WO2000001813 A3 WO 2000001813A3 CA 9900604 W CA9900604 W CA 9900604W WO 0001813 A3 WO0001813 A3 WO 0001813A3
Authority
WO
WIPO (PCT)
Prior art keywords
androgen
independent activation
androgen receptor
receptor
activation
Prior art date
Application number
PCT/CA1999/000604
Other languages
French (fr)
Other versions
WO2000001813A2 (en
Inventor
Marianne D Sadar
Nicholas Bruchovsky
Peter W Gout
Robert Snoek
Nasrin R Mawji
Original Assignee
Univ British Columbia
Marianne D Sadar
Nicholas Bruchovsky
Peter W Gout
Robert Snoek
Nasrin R Mawji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Marianne D Sadar, Nicholas Bruchovsky, Peter W Gout, Robert Snoek, Nasrin R Mawji filed Critical Univ British Columbia
Priority to CA002302169A priority Critical patent/CA2302169A1/en
Priority to AU44943/99A priority patent/AU4494399A/en
Publication of WO2000001813A2 publication Critical patent/WO2000001813A2/en
Publication of WO2000001813A3 publication Critical patent/WO2000001813A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Androgen-independent activation of the androgen receptor is localized to the region of amino acids 234-391 of human androgen receptor protein. Peptides derived and nucleic acids encoding such peptides are provided. The peptides are useful as activation domains, as inhibitors of androgen-independent activation of androgen receptor, for screening compounds that affect androgen-independent activation of androgen receptor, and for treatment of androgen mediated diseases such as prostate cancer. Methods for screening compounds affecting androgen-independent activation of androgen receptor are also provided.
PCT/CA1999/000604 1998-06-30 1999-06-30 Peptide inhibitors of androgen-independent activation of androgen receptor WO2000001813A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002302169A CA2302169A1 (en) 1998-06-30 1999-06-30 Inhibitors of androgen-independent activation of androgen receptor
AU44943/99A AU4494399A (en) 1998-06-30 1999-06-30 Inhibitors of androgen-independent activation of androgen receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9187198P 1998-06-30 1998-06-30
US60/091,871 1998-06-30

Publications (2)

Publication Number Publication Date
WO2000001813A2 WO2000001813A2 (en) 2000-01-13
WO2000001813A3 true WO2000001813A3 (en) 2000-04-13

Family

ID=22230037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000604 WO2000001813A2 (en) 1998-06-30 1999-06-30 Peptide inhibitors of androgen-independent activation of androgen receptor

Country Status (3)

Country Link
AU (1) AU4494399A (en)
CA (1) CA2302169A1 (en)
WO (1) WO2000001813A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960474B2 (en) 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003018987A (en) * 2001-06-25 2003-01-21 Okazaki National Research Institutes Transgenic cell and method for detecting disturbing material by using the same
US20100189776A1 (en) 2007-03-16 2010-07-29 Cancer Research Technology Ltd Anti-androgen peptides and uses thereof in cancer therapy
US20100291086A1 (en) * 2007-09-11 2010-11-18 Christopher Hovens Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
FR2938334A1 (en) * 2008-11-13 2010-05-14 Galderma Res & Dev MODULATORS OF ADFP IN THE TREATMENT OF ACNE, SEBORRHEA DERMATITIS OR HYPERSEBORRHEA
CA2728219C (en) 2008-07-02 2016-12-13 British Columbia Cancer Agency Branch Diglycidic ether derivative therapeutics and methods for their use
AU2009284668B2 (en) 2008-08-22 2015-07-09 British Columbia Cancer Agency Branch Small molecule inhibitors of N-terminus activation of the androgen receptor
CA2786319C (en) 2010-01-06 2019-03-12 British Columbia Cancer Agency Branch Bisphenol derivatives and their use as androgen receptor activity modulators
EP2693875A4 (en) 2011-04-08 2014-10-22 British Columbia Cancer Agency BISPHENOL COMPOUNDS AND METHODS OF USE
US20130045204A1 (en) 2011-08-19 2013-02-21 The University Of British Columbia Fluorinated bisphenol ether compounds and methods for their use
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
GB2513615A (en) 2013-05-01 2014-11-05 Cancer Rec Tech Ltd Medical use
PE20160091A1 (en) 2013-05-10 2016-03-03 British Columbia Cancer Agency Branch ESTER DERIVATIVES OF ANDROGEN RECEIVER MODULATORS AND METHODS FOR THEIR USE
SG11201601431VA (en) 2013-09-09 2016-03-30 British Columbia Cancer Agency Halogenated compounds for cancer imaging and treatment and methods for their use
CA2948643C (en) 2014-05-30 2022-09-06 British Columbia Cancer Agency Branch Androgen receptor modulators and methods for their use
EP3245193B1 (en) 2015-01-13 2021-12-08 British Columbia Cancer Agency Branch Heterocyclic compounds for cancer imaging and treatment and methods for their use
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
SG11201900153XA (en) * 2016-08-08 2019-02-27 Olipass Corp Androgen receptor antisense oligonucleotides
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
NZ774611A (en) 2018-10-18 2025-03-28 Essa Pharma Inc Androgen receptor modulators and methods for their use
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
KR20230004498A (en) 2020-04-17 2023-01-06 에싸 파마 아이엔씨. Solid Forms of N-Terminal Domain Androgen Receptor Inhibitors and Uses Thereof
WO2023046283A1 (en) 2021-09-22 2023-03-30 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Compounds and their use in a method for modulating ar (androgen receptor) transcriptional activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009791A1 (en) * 1988-04-14 1989-10-19 University Of North Carolina At Chapel Hill Dna encoding androgen receptor protein
EP0577932A2 (en) * 1992-05-08 1994-01-12 American Cyanamid Company Development of a mechanism-based screen to identify androgen receptor agonists and antagonists
WO1997030074A1 (en) * 1996-02-16 1997-08-21 Cytogen Corporation Isolation and use of sh3 binding peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009791A1 (en) * 1988-04-14 1989-10-19 University Of North Carolina At Chapel Hill Dna encoding androgen receptor protein
EP0577932A2 (en) * 1992-05-08 1994-01-12 American Cyanamid Company Development of a mechanism-based screen to identify androgen receptor agonists and antagonists
WO1997030074A1 (en) * 1996-02-16 1997-08-21 Cytogen Corporation Isolation and use of sh3 binding peptides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHAMBERLAIN, N L ET AL.,: "Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 43, 25 October 1996 (1996-10-25), pages 26772 - 26778, XP002130096 *
CULIG Z ET AL.,: "Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor", CANCER RESEARCH, vol. 54, 15 October 1994 (1994-10-15), pages 5474 - 5478, XP000867802 *
DE RUITER PE ET AL.,: "Synergism between androgens and protein kinase-C on androgen regulated gene expression", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 110, 1995, pages r1 - r6, XP000874779 *
JENSTER G ET AL.,: "Identification of two transcription activation units in the N-terminal domain of the human androgen receptor.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 13, 31 March 1995 (1995-03-31), pages 7341 - 7346, XP000867758 *
JIA L D ET AL: "Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells", STEROIDS: STRUCTURE, FUNCTION, AND REGULATION,US,ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, vol. 61, no. 9, 1996, pages 531-539, XP004070285, ISSN: 0039-128X *
NAZARETH LV AND WEIGEL NL: "Activation of human androgen receptor through a protein kinase A signaling pathway", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, 1996, pages 19900 - 19907, XP002130095 *
SADAR MD: "Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 12 March 1999 (1999-03-12), pages 7777 - 7783, XP002130097 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960474B2 (en) 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator

Also Published As

Publication number Publication date
AU4494399A (en) 2000-01-24
CA2302169A1 (en) 2000-01-13
WO2000001813A2 (en) 2000-01-13

Similar Documents

Publication Publication Date Title
WO2000001813A3 (en) Peptide inhibitors of androgen-independent activation of androgen receptor
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
MY120693A (en) Human bikunin
HUP0002095A2 (en) Compounds for immunotherapy of prostate cancer and methods for their use
CA2184908A1 (en) Human osteoclast-derived cathepsin
WO2001036640A3 (en) Human fgf-21 gene and gene expression products
EP1194164B8 (en) Prion protein peptides and uses thereof
EP2258383A3 (en) Antigenic peptides derived from telomerase
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
ATE299510T1 (en) PEPTIDES AS POTASSIUM CHANNEL ACTIVators
WO2003016342A3 (en) Tumor antigens for prevention and/or treatment of cancer
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
UA72875C2 (en) Novel proteins which bind human <sub>0100090000039d00000002001c00000000000500000009020000000005000000020101000000050000000102ffffff00050000002e0118000000050000000b0200000000050000000c02000240011200000026060f001a00ffffffff000010000000c0ffffffc6ffffff00010000c60100000b00000026060f000c004d61746854797065000050001c000000fb0280fe0000000000009001000000020002001053796d626f6c0077400000006b0d0a974c53f5775553f5770100000000003000040000002d01000008000000320a600128000100000062790a00000026060f000a00ffffffff0100000000001c000000fb021000070000000000bc02000000cc0102022253797374656d000000000a000000040000000000ffffffff0100000000003000040000002d01010004000000f0010000030000000000-amyloid peptide, polynucleotides which encode theM
WO2002094859A3 (en) Mage-a1 peptides for treating or preventing cancer
AU7525398A (en) Inhibitors for urokinase receptor
WO2002034915A3 (en) Preferred segments of neural thread protein and methods of using the same
DK0938329T3 (en) Immunogenic TLP composition
BR0008917A (en) Compounds
WO2000024771A3 (en) Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
HRP970693B1 (en) Cycloalkyl inhibitors of protein farnesyltransferase
WO2002030977A3 (en) Egf motif protein, egfl6 materials and methods
DE60120187D1 (en) SHORTEN BARD1 PROTEIN AND ITS DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
ATE362531T1 (en) INTERNAL RIBOSOME ENTRY SITE (IRES), VECTOR THAT CONTAINS IT AND ITS THERAPEUTIC USE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Kind code of ref document: A

Ref document number: 2302169

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 09515886

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase